We are a dedicated team of biotechnology and software engineers committed to addressing the global challenge of frequent respiratory disease outbreaks. By harnessing the power of cutting-edge technologies, we develop pre-symptomatic diagnostic devices for viral infections as an alternative to existing analytical platforms that are bulky, expensive and require qualified personnel to interpret the results.
Our device allows the integration of multiple detection modules with different capture elements to simultaneously detect multiple airborne viruses, such as SARS-CoV-2, respiratory syncytial virus, or influenza.
Unlike existing aerosol analyzers necessitating additional biochemical assays for pathogen identification, our technology leverages highly specific antibody-antigen binding. This approach allows for automatic and accurate identification of pathogens without the need for manual intervention.
The lower cost and simple maintenance make our platform affordable for individuals, small enterprises, and healthcare facilities, as opposed to commercially available biodefense devices targeted at large military actors.
CEO
CIO
R&D Engineer